Dr. Djulbegovic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
MUSC Hematology Oncology
39 Sabin St, MSC 635
Charleston, SC 29425Phone+1 843-792-2646Fax+1 843-792-0644
Education & Training
- University of Louisville School of MedicineFellowship, Hematology and Medical Oncology, 1988 - 1991
- University of Sarajevo FOMClass of 1976
- University of Louisville School of MedicineResidency, Internal Medicine
Certifications & Licensure
- FL State Medical License 1998 - 2026
- CA State Medical License 2017 - 2025
- IN State Medical License 1994 - 2025
- KY State Medical License 1990 - 2025
- SC State Medical License 2023 - 2025
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Publications & Presentations
PubMed
- 157 citationsHigh-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized ...John Koreth, Corey Cutler, Benjamin Djulbegovic, Rajesh Behl, Robert L. Schlossman
Biology of Blood and Marrow Transplantation. 2007-02-01 - 91 citationsDefining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature ReviewClark DuMontier, Kah Poh Loh, Paul A. Bain, Rebecca A. Silliman, Tammy T. Hshieh
Journal of Clinical Oncology. 2019-11-01 - 66 citationsPublished methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocolsRahul Mhaskar, Benjamin Djulbegovic, Anja Magazin, Heloisa P. Soares, Ambuj Kumar
Journal of Clinical Epidemiology. 2012-06-01
Journal Articles
- Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-Risk Cytogenetic FactorsSusan Bal, Benjamin Djulbegovic, Saad Z Usmani, JAMA Oncology
- Bisphosphonates for Patients Diagnosed with Multiple MyelomaBenjamin Djulbegovic, MD, JAMA
Press Mentions
- New Report Assesses COVID-19’S Trajectory and Implications for Medicare, Social SecurityJune 3rd, 2021
- Use of a Decision Tree and Omics Data May Help Improve Survival Rates in Advanced NSCLCSeptember 2nd, 2020
- US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical TrialsSeptember 11th, 2019
- Join now to see all
Committees
- Member, Expert Panel, AABB 2015 - Present
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: